Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Locally Advanced Rectal Cancer Clinical Trial

Official title:

The Efficacy and Safety of Preoperative Neoadjuvant Chemoradiation Combined With PD-1 Inhibitor and PCSK9 Inhibitor in the Treatment of pMMR/MSS Locally Advanced Middle and Low Rectal Cancer: a Multicenter Study, Prospective, Randomized Controlled Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06304987
• Other study ID #: BFH-niCRT-05
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: April 2024
• Est. completion date: May 2026

Study information

• Verified date: March 2024
• Source: Beijing Friendship Hospital
• Contact: Zhongtao Zhang, MD
• Phone: +86 13801060364
• Email: Zhangzht[@]ccmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, prospective, randomized controlled study to evaluate the effectiveness and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and PCSK9 inhibitor in the treatment of patients with pMMR/MSS locally advanced middle and low rectal cancer.

Description:

This study included patients with locally advanced low rectal cancer as research subjects, and evaluated the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor (Sintilimab) and PCSK9 inhibitor (Tafolecimab) or neoadjuvant chemoradiotherapy combined with PD -1 (Sintilimab) for patients with locally advanced rectal cancer. The primary endpoints of the study are clinical complete response (cCR) (including imaging and endoscopic complete response) and pathological complete response (pCR). Secondary endpoints are major pathological response rate (MPR), objective response rate (ORR), disease-free survival (DFS), overall survival (OS), organ preservation rate (OPR), and neoadjuvant rectal (NAR) score, quality of life score (QoL), safety and tolerability.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: May 2026
• Est. primary completion date: April 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Sign a written informed consent form and voluntarily join this study;

2. Age 18-75 years old, male or female;

3. Pathologically confirmed adenocarcinoma of the rectum;

4. Clinically staged as II~III stage by MRI (according to the 8th edition of AJCC);

5. Tumor lower edge distance from the anal margin =10cm;

6. Able to undergo surgical resection;

7. Able to swallow pills normally;

8. ECOG PS 0-1;

9. No prior anti-tumor therapy for rectal cancer, including radiotherapy, chemotherapy, surgery, etc.;

10. Planning to undergo surgical treatment after completing neoadjuvant therapy;

11. No contraindications for surgery;

12. Normal major organ function, including:

1. Blood routine examination (no blood or blood products transfusion within 14 days before the first treatment, no use of G-CSF or other hematopoietic stimulating factors for correction):

• Neutrophil count =1.5×109/L

• Platelet count =100×109/L

• Hemoglobin =90 g/L

2. Blood biochemistry:

• Total bilirubin =1.5×ULN

• ALT = 2.5×ULN, AST = 2.5×ULN,

• Serum creatinine =1.5×ULN, or creatinine clearance rate =50 mL/min (Cocheroft-Gault formula)

3. Coagulation function:

• International normalized ratio (INR) = 1.5×ULN

• Activated partial thromboplastin time (APTT) = 1.5×ULN

• Female subjects of childbearing potential should have a negative serum pregnancy test within 72 hours before the start of study drug administration, and effective contraception should be used during the trial period and for at least 3 months after the last dose (such as intrauterine devices, contraceptive pills, or condoms); for male subjects with female partners of childbearing potential, effective contraception should be used during the trial period and for 3 months after the last dose.

Exclusion Criteria:

1. History of allergy to monoclonal antibodies, PD-1 monoclonal antibodies, capecitabine, or oxaliplatin;

2. History of receiving or currently receiving any of the following treatments:

1. Any surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc., for tumors;

2. Use of immunosuppressive drugs or systemic steroid therapy to achieve immunosuppression (dose >10mg/day prednisone or equivalent) within 2 weeks before the first use of the study drug; inhalation or local use of steroids and adrenal cortical hormone replacement therapy with a dose >10mg/day prednisone or equivalent is allowed in the absence of active autoimmune diseases;

3. Receipt of attenuated live vaccines within 4 weeks before the first use of the study drug;

4. Underwent major surgery or had severe trauma within 4 weeks before the first use of the study drug;

3. Active autoimmune diseases or history of autoimmune diseases, including but not limited to: interstitial pneumonia, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism (considered for inclusion after hormone replacement therapy); psoriasis or childhood asthma/allergies that have completely resolved and do not require any intervention in adulthood may be considered for inclusion, but patients requiring bronchodilators for medical intervention are not eligible for inclusion;

4. History of immunodeficiency, including HIV positive, or acquired or congenital immunodeficiency diseases, or history of organ transplantation or allogeneic bone marrow transplantation;

5. Presence of poorly controlled clinical symptoms or diseases of the heart, including but not limited to: (1) NYHA class II or above heart failure, (2) unstable angina pectoris, (3) myocardial infarction within the past year, (4) clinically significant supraventricular or ventricular arrhythmias that have not been clinically intervened or poorly controlled after clinical intervention;

6. Severe infection (CTCAE > grade 2) within 4 weeks before the first use of the study drug, such as severe pneumonia requiring hospitalization, septicemia, complications of infection, etc.; baseline chest imaging suggests active pulmonary inflammation, presence of symptoms and signs of infection within 14 days before the first use of the study drug or requiring oral or intravenous antibiotic therapy, except for prophylactic use of antibiotics;

7. Active pulmonary tuberculosis infection found through medical history or CT examination, or a history of active pulmonary tuberculosis infection within the past year before enrollment, or a history of active pulmonary tuberculosis infection more than 1 year ago but without proper treatment;

8. Active hepatitis B (HBV DNA = 2000 IU/mL or 104 copies/mL), hepatitis C (HCV antibody positive, and HCV RNA higher than the lower limit of detection of the assay);

9. Diagnosed with other malignant tumors within 5 years before the first use of the study drug, unless they have a low risk of metastasis or death (5-year survival rate > 90%), such as adequately treated basal cell carcinoma or squamous cell skin cancer or carcinoma in situ of the cervix, may be considered for inclusion;

10. Pregnant or lactating women;

11. Judged by the investigator to have other factors that may lead to premature termination of the study, such as having other serious diseases (including mental illnesses) requiring concomitant treatment, alcoholism, drug abuse, family or social factors, factors that may affect the safety or compliance of the subject.

Related Conditions & MeSH terms

• Locally Advanced Rectal Cancer
• Rectal Neoplasms

Intervention

Combination Product:
• Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor
In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.
• Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor
In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.

Locations

Country	Name	City	State
China	Beijing Friendship Hospital	Beijing	Beijing
China	Beijing Friendship Hospital, Capital Medical University	Beijing	Beijing

Sponsors (4)

Lead Sponsor	Collaborator
Beijing Friendship Hospital	Changhai Hospital, Peking Union Medical College Hospital, Peking University Cancer Hospital & Institute

Country where clinical trial is conducted

China, 

References & Publications (4)

Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003 Jun;34(2):154-6. doi: 10.1038/ng1161. — View Citation

Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005 Feb;37(2):161-5. doi: 10.1038/ng1509. Epub 2005 Jan 16. Erratum In: Nat Genet. 2005 Mar;37(3):328. — View Citation

Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, Xie L, Huang Q, Li F, Li CY. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020 Dec;588(7839):693-698. doi: 10.1038/s41586-020-2911-7. Epub 2020 Nov 11. — View Citation

Yang Z, Zhang X, Zhang J, Gao J, Bai Z, Deng W, Chen G, An Y, Liu Y, Wei Q, Han J, Li A, Liu G, Sun Y, Kong D, Yao H, Zhang Z. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial). BMC Cancer. 2022 Apr 27;22(1):462. doi: 10.1186/s12885-022-09554-9. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CR	complete response rate=(number of pathological complete responses + number of clinical complete responses)/total number of patients	pCR :within 10 days after surgery;cCR :12-13 weeks after radiotherapy ends
Primary	AE rate	Adverse event rate	during treatment
Secondary	NAR score	Neoadjuvant rectal(NAR)score:It is based on the scoring criteria of preoperative treatment	within 10 days after surgery
Secondary	OPR	organ preservation rate	immediately after surgery
Secondary	ORR	objective response rate	within 10 days after surgery
Secondary	immune-related adverse event rate	adverse event rate that is deemed to be associated with PD-1 inhibition	up to 30th day after surgery